莎普爱思品牌怎么样 申请店铺

我要投票 莎普爱思在滴眼液行业中的票数:303 更新时间:2025-05-17
莎普爱思是哪个国家的品牌?「莎普爱思」是 浙江莎普爱思药业股份有限公司 旗下著名品牌。该品牌发源于浙江,由创始人陈德康在2000-07-17期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力莎普爱思品牌出海!将品牌入驻外推网,定制莎普爱思品牌推广信息,可以显著提高莎普爱思产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

莎普爱思怎么样

公司自1978年建厂以来,经历了从“国营浙江平湖制药厂”转制成“浙江平湖制药厂(股份合作)”到“浙江平湖莎普爱思制药有限公司”,再到“浙江莎普爱思制药有限公司”,最终于2008年12月15日更名为“浙江莎普爱思药业股份有限公司”,目前注册资金为4900万元人民币。

公司作为一家专业从事药品研发、生产、经营的综合性制药企业,先后被列为“国家高新技术企业”、“浙江省百家最具投资价值企业”、“浙江省千家成长之星企业”、“浙江省级企业技术中心”、“省级高新技术研究开发中心”、“浙江省标准创新型企业”、“嘉兴市重点企业技术创新团队”、“院士专家工作站”等多项荣誉称号。

目前公司拥有大容量注射剂(玻璃瓶、塑料瓶和多层共挤膜袋)、口服溶液剂、滴眼剂、片剂(含头孢菌素类)、硬胶囊剂(含头孢菌素类)、栓剂、颗粒剂(含头孢菌素类)、干混悬剂(含头孢菌素类)、冲洗剂共10个剂型,近百种规格的产品批准文号。抗白内障新药“莎普爱思”滴眼液和抗青光眼新药“达靓”滴眼液被列入“国家火炬计划项目”。“莎普爱思”滴眼液还荣获国家重点科技攻关项目、国家重点新产品、浙江省名牌产品等多个称号,是国内第一个国家二类眼科专科新药。

几十年来,公司凭着优质的产品,良好的信誉,在市场竞争日益激烈的情况下,赢得了市场,产品销往全国各地,取得了良好的经济效益。近年来公司的产品销量与销售额都呈现出逐年增涨的态势,是平湖市重点扶持的股改上市企业。

在竞争激烈的医药市场中,我公司始终坚持科技兴业、加强管理、保证质量,不断推出各种自主研发的新产品。公司秉承“科技创新、求是进取、优质高效、和谐健康”的企业精神,不断寻求创新与突破,逐步使公司成为现代化、高科技制药企业。

莎普爱思的未来将坚持以市场为导向,发展为主题,科技创新为核心。以保护和增进人民健康、提高人民福祉为目标。我们确信莎普爱思的无限“关爱”会遍及中国,走向世界。

Since its establishment in 1978, the company has gone through the transformation from "state-owned Zhejiang Pinghu pharmaceutical factory" to "Zhejiang Pinghu pharmaceutical factory (joint stock cooperation)" to "Zhejiang Pinghu sapais Pharmaceutical Co., Ltd." and then to "Zhejiang sapais Pharmaceutical Co., Ltd." and finally changed its name to "Zhejiang sapais pharmaceutical Co., Ltd." on December 15, 2008, with the current registered capital of 49 million yuan RMB. As a comprehensive pharmaceutical enterprise specializing in drug R & D, production and operation, the company has been listed as "national high-tech enterprise", "one hundred enterprises with the most investment value in Zhejiang Province", "one thousand growth star enterprises in Zhejiang Province", "Zhejiang provincial enterprise technology center", "provincial high-tech research and development center", "Zhejiang standard innovation enterprise" "Jiaxing key enterprise technology innovation team", "academician expert workstation" and other honorary titles. At present, the company has 10 dosage forms of large capacity injection (glass bottles, plastic bottles and multi-layer coextrusion film bags), oral solution, eye drops, tablets (including cephalosporins), hard capsules (including cephalosporins), suppositories, granules (including cephalosporins), dry suspension (including cephalosporins), washing agents, and approval numbers of nearly 100 specifications of products. The new anti cataract drug "sapais" eye drops and the new anti glaucoma drug "Daliang" eye drops are listed in the "National Torch Program project". "Saps eye drops" also won the titles of national key scientific and technological research projects, national key new products, Zhejiang famous brand products, etc., and is the first national class II ophthalmic specialty new drug in China. In the past few decades, with its high quality products and good reputation, the company has won the market and sold its products to all parts of the country under the increasingly fierce market competition, and achieved good economic benefits. In recent years, the sales volume and sales volume of the company have been increasing year by year. It is a listed company supported by Pinghu City. In the highly competitive pharmaceutical market, our company always adheres to the development of science and technology, strengthening management, ensuring quality, and constantly launches various new products independently researched and developed. The company adheres to the enterprise spirit of "scientific and technological innovation, truth-seeking and enterprising, high-quality and efficient, harmonious and healthy", constantly seeks innovation and breakthrough, and gradually makes the company become a modern, high-tech pharmaceutical enterprise. In the future, SAPS will adhere to the market-oriented, development oriented theme and technological innovation as the core. With the goal of protecting and promoting people's health and improving people's well-being. We are sure that the infinite "love" of sapeus will spread all over China and go to the world.

本文链接: https://brand.waitui.com/a5a71ec58.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

华泰证券:看好海外燃气轮机主机的量价齐升

华泰证券发布最新研报称,根据McCoy统计,2025年一季度全球燃气轮机新增订单同比增长36%至20GW。海外大选后能源政策右转、中东油转气、AI电源需求多因素推动全球燃气轮机景气度继续上行,5月初西班牙大停电或引发对电源结构中灵活、同步机组不足的反思。看好海外燃气轮机主机的量价齐升,且有望带动国内热端叶片、冷端缸体等部件企业出口机遇。(财联社)

2小时前

穆迪下调美国主权信用评级

据央视新闻,国际信用评级机构穆迪16日宣布,由于美国政府债务和利率支付比例增加,该机构决定将美国主权信用评级从Aaa下调至Aa1,同时将美国主权信用评级展望从“负面”调整为“稳定”。

2小时前

魏牌全新高山正式上市

36氪获悉,近日以“开启MPV家庭新时代”为主题的魏牌全新高山上市发布会在保定举行。此次发布会正式推出全新高山8/9两款车型,通过打造“有品位的家、舒适的家、安全的家、智能的家、健康的家”五大价值场景,重新界定了家庭 MPV 行业标准。此外,发布会正式公布了全新高山8/9最终售价,其中,全新高山8官方指导价30.98万元,全新高山9官方指导价35.38万元。

2小时前

清华大学五道口金融学院院长焦捷:“五篇大文章”构成中国金融高质量发展新驱动力

据上证报,5月17日,2025清华五道口全球金融论坛在深圳举行。清华大学五道口金融学院院长焦捷表示,多年来,中国一直是世界经济增长的主要贡献者和稳定锚。中国坚持真正的多边主义,积极参与全球经济治理,是经济全球化和贸易自由化的倡导者;并正从全球治理的规则追随者逐步转向制度改革者。中国致力于以高质量发展的确定性应对外部环境急剧变化的不确定性。当前,中国正以新质生产力破解增长瓶颈,推动经济高质量发展。金融是“国之大者”,关系中国式现代化建设全局。中央金融工作会议首次系统提出“做好科技金融、绿色金融、普惠金融、养老金融、数字金融五篇大文章”,“五篇大文章”构成了中国金融高质量发展的新驱动力。

2小时前

华泰证券:看好海外燃气轮机主机的量价齐升

华泰证券发布最新研报称,根据McCoy统计,2025年一季度全球燃气轮机新增订单同比增长36%至20GW。海外大选后能源政策右转、中东油转气、AI电源需求多因素推动全球燃气轮机景气度继续上行,5月初西班牙大停电或引发对电源结构中灵活、同步机组不足的反思。看好海外燃气轮机主机的量价齐升,且有望带动国内热端叶片、冷端缸体等部件企业出口机遇。

2小时前

本页详细列出关于莎普爱思的品牌信息,含品牌所属公司介绍,莎普爱思所处行业的品牌地位及优势。
咨询